261 related articles for article (PubMed ID: 34630436)
1. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.
Zou J; Jing H; Zhang X; Liu Y; Zhao Z; Duan L; Yuan Y; Chen Z; Gou Q; Xiong Q; Li S; Yang F; Zeng H; Zou Q; Zhang J
Front Immunol; 2021; 12():757691. PubMed ID: 34630436
[TBL] [Abstract][Full Text] [Related]
2. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
Wang Y; Wang L; Cao H; Liu C
J Med Virol; 2021 Feb; 93(2):892-898. PubMed ID: 32691875
[TBL] [Abstract][Full Text] [Related]
8. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
9. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
10. A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice.
Coria LM; Saposnik LM; Pueblas Castro C; Castro EF; Bruno LA; Stone WB; Pérez PS; Darriba ML; Chemes LB; Alcain J; Mazzitelli I; Varese A; Salvatori M; Auguste AJ; Álvarez DE; Pasquevich KA; Cassataro J
Front Immunol; 2022; 13():844837. PubMed ID: 35296091
[TBL] [Abstract][Full Text] [Related]
11. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
12. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
[TBL] [Abstract][Full Text] [Related]
13. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
Front Immunol; 2021; 12():637982. PubMed ID: 33777030
[TBL] [Abstract][Full Text] [Related]
14. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
Huang J; Wang W; Li H; Bai Y; Song Y; Jiao C; Jin H; Huang P; Zhang H; Xia X; Yan F; Li Y; Wang H
Antiviral Res; 2024 Jul; 227():105905. PubMed ID: 38740191
[TBL] [Abstract][Full Text] [Related]
15. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
16. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.
Burnett DL; Jackson KJL; Langley DB; Aggrawal A; Stella AO; Johansen MD; Balachandran H; Lenthall H; Rouet R; Walker G; Saunders BM; Singh M; Li H; Henry JY; Jackson J; Stewart AG; Witthauer F; Spence MA; Hansbro NG; Jackson C; Schofield P; Milthorpe C; Martinello M; Schulz SR; Roth E; Kelleher A; Emery S; Britton WJ; Rawlinson WD; Karl R; Schäfer S; Winkler TH; Brink R; Bull RA; Hansbro PM; Jäck HM; Turville S; Christ D; Goodnow CC
Immunity; 2021 Dec; 54(12):2908-2921.e6. PubMed ID: 34788600
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
18. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model.
Wongnak R; Brindha S; Oba M; Yoshizue T; Islam MD; Islam MM; Takemae H; Mizutani T; Kuroda Y
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893549
[TBL] [Abstract][Full Text] [Related]
19. Hydrogel-Based Slow Release of a Receptor-Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS-CoV-2.
Gale EC; Powell AE; Roth GA; Meany EL; Yan J; Ou BS; Grosskopf AK; Adamska J; Picece VCTM; d'Aquino AI; Pulendran B; Kim PS; Appel EA
Adv Mater; 2021 Dec; 33(51):e2104362. PubMed ID: 34651342
[TBL] [Abstract][Full Text] [Related]
20. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
